Lifecore Biomedical, Inc. - Common Stock LFCR 深 滬
已收盤 12-24 16:00:00 美东时间
8.25
+0.190
+2.36%
華盛通- 最 高8.33
- 今 開8.01
- 成交量 5.21万股
- 最 低 8.00
- 昨 收 8.06
- 總市值 3.09亿
- 52周最高 8.85
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 4.76
- 委 比 61.98%
- 總股本 3746.64万
- 歷史最高 15.96
- 量 比 0.21
- 振 幅 4.09%
- 歷史最低 1.52
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lifecore Biomedical Lands Major Global Pharma Deal to Make Injectable Drug in the US
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO master services agreement with a new large
12-17 20:09
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Lifecore Biomedical has signed a CDMO master services agreement with a global pharmaceutical customer. The agreement involves development services and tech transfer for an injectable product, with plans to transfer commercial supply to Lifecore's facilities. This is the second agreement with a multinational pharma company in three months. Based on current revenue, the new partner has potential to become one of Lifecore's top five commercial custo...
12-17 12:00
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Lifecore Biomedical, Inc. (NASDAQ: LFCR) will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California. The company’s CEO, Paul Josephs, and CFO, Ryan Lake, will attend 1-on-1 meetings. Lifecore, a leading CDMO specializing in sterile injectable pharmaceuticals and hyaluronic acid manufacturing, has over 40 years of experience. For more information, visit www.lifecore.com.
12-16 12:00
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its participation in two upcoming investor conferences. The company’s CEO, Paul Josephs, will deliver a presentation at the Jefferies 2025 Global Healthcare Conference in London on November 18, 2025. Additionally, Josephs will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville on November 20, 2025. Both events will include webcasts accessible via Lifecore’s i...
11-11 21:05
Greenhaven Road Capital Main Fund exits IWGFF, ALTG, SOC
The Greenhaven Road Capital Main Fund has underperformed with a return of -9% during Q3 2025. During the third quarter, the fund exited International Workplace (OTCPK:IWGFF), Alta Equipment Group (NYS...
11-11 00:46
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading global pharmaceutical
10-29 19:23
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore Biomedical has signed two agreements: one to transfer commercial manufacturing of a leading injectable pharmaceutical product from a global pharmaceutical company, making it the new supplier, and another with an early-stage biotech company for pre-clinical formulation development. These signings highlight Lifecore's growing reputation and support its growth strategies, including expanding CDMO business and domestic manufacturing capacity...
10-29 11:00
LifeStance to Present at the UBS Global Healthcare Conference
LifeStance Health Group, a leading U.S. provider of outpatient mental health care, announced that CEO Dave Bourdon will present at the UBS Global Healthcare Conference on November 10, 2025, at 4:15 p.m. ET. The presentation, moderated by Kevin Caliendo, will be webcast live and available on the company’s Investor Relations website at investor.lifestance.com. A replay will also be accessible post-event. LifeStance, founded in 2017, operates across...
10-28 20:10
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Lifecore Biomedical and PolyPeptide Laboratories have signed a collaboration agreement to offer integrated, end-to-end solutions for peptide-based pharmaceutical customers in the U.S. The partnership combines PolyPeptide's peptide manufacturing expertise with Lifecore's formulation, fill/finish, and packaging capabilities, aiming to accelerate development timelines, reduce costs, and ensure a reliable U.S.-based supply chain. The collaboration wi...
10-28 11:00
